DexCom, Inc. (DXCM)
DexCom makes clever wearable sensors that help people with diabetes track their blood sugar levels in real-time without needing constant finger pricks.
Is DexCom, Inc. a good stock for a UK beginner?
The honest version: DexCom makes clever wearable sensors that help people with diabetes track their blood sugar levels in real-time without needing constant finger pricks.
Over about 2 years to 2026-07-31. This is the share price only; any dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.
Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.
Widespread adoption of sensors for non-insulin users
Technological obsolescence or major product recalls
What does DexCom, Inc. do?
DexCom is a leader in continuous glucose monitoring, selling small, disposable sensors that send blood sugar data straight to a smartphone. Its earnings come from selling these sensors and the accompanying transmitters, which need to be replaced regularly. How they fend off rival medical device makers and keep expanding their user base worldwide is what to follow.
On our factor screen it looks strongest on momentum and quality, and weakest on income.
- !Pays no dividend - the whole return rides on the share price
- ✓Growing - revenue up about 13% over the year
- ✓Very profitable - turns about 20% of sales into profit
- !High P/E of 33 - big growth is already priced in
- ✓Strong return on shareholder money (ROE 38%)
- Quality screens high (74/100)
- Momentum screens high (76/100)
- High profit margins on their core products
- Strong growth in earnings compared to the previous year
- Essential technology with a loyal customer base
- Value screens low (29/100)
- Income screens low (16/100)
- Intense competition from other medical device companies
- Reliance on insurance companies to cover the cost of sensors
- Potential for regulatory hurdles in new international markets
What do DexCom, Inc.'s numbers mean?
How much money does DexCom, Inc. make?
Revenue and profit by quarter, and how much of each sale turns into profit.
Does DexCom, Inc. pay a dividend?
No - DexCom, Inc. doesn't currently pay a dividend, so the whole return would rest on the share price. Plenty of growing companies reinvest their profits instead of paying them out - neither approach is better or worse, they're just different.
When does DexCom, Inc. report earnings, and how did recent quarters go?
DexCom, Inc. is next scheduled to report on about 2026-10-29 - dates can move, and we don't predict results; this just tells you when to look.
Each quarter a company reports its results against what analysts expected. ‘Beating’ or ‘missing’ is about that expectation, not whether the business is doing well in absolute terms.
| Reported | Expected EPS: The earnings per share analysts expected for the quarter - the average of their forecasts. 'Beating' or 'missing' is measured against this number. | Actual EPS | vs expected |
|---|---|---|---|
| 2026-07-30 | $0.61 | $0.70 | Beat +15% |
| 2026-04-30 | $0.47 | $0.56 | Beat +19% |
| 2026-02-12 | $0.65 | $0.68 | Beat +4% |
| 2025-10-30 | $0.57 | $0.61 | Beat +8% |
| 2025-07-30 | $0.44 | $0.48 | Beat +8% |
| 2025-05-01 | $0.33 | $0.32 | Missed -3% |
Across the last 6 quarters here, DexCom, Inc. came in ahead of what analysts expected 5 times. One quarter is noise, not a trend.
See who else reports over the next two weeks →
Reported vs expected earnings per share (EPS) from published results; the expectation is the analyst consensus, not our view. Report dates are estimates that can move.
More in Healthcare
Eli Lilly
West Pharmaceutical Services, Inc.
Incyte Corporation
The Cigna Group
Zimmer Biomet Holdings, Inc.
Moderna, Inc.
Gilead Sciences, Inc.
Regeneron Pharmaceuticals, Inc.What are the scenarios for DexCom, Inc.?
An illustrative range for the year ahead, with the assumption behind each case — not a prediction or a price target.
What are the pros and cons of DexCom, Inc.?
How many points the write-up makes each way — a balance check, not a score or verdict.
- High profit margins on their core products
- Strong growth in earnings compared to the previous year
- Essential technology with a loyal customer base
- No dividend payments for shareholders
- High price-to-book ratio suggests the shares are priced at a premium to their physical assets
- The share price has been volatile over the last year
- Intense competition from other medical device companies
- Reliance on insurance companies to cover the cost of sensors
- Potential for regulatory hurdles in new international markets
The write-up's own warning lights — if these start happening, the case above changes.
- A significant drop in the company's profit margins
- Loss of market share to a cheaper or more effective competitor
Built from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →
This plain-English summary was auto-generated on 2026-08-01 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.